Cabergoline originates from which country? This article will help you understand!

Cabergoline is a dopamine receptor agonist, mainly used to treat diseases such as hyperprolactinemia (HPRL). Cabergoline was originally developed by the Italian company Sanofi. Sanofi is a leading global pharmaceutical company headquartered in France, but its early research and development activities and preliminary work on many of its key drugs are conducted in Italy. Thus, the origins of cabergoline can be traced to Italian scientific research.

Sanofi was founded in 2004 as a result of the merger of the original Sanofi-Aventis and another pharmaceutical company Aventis. Sanofi is committed to developing drugs for the treatment of cancer, cardiovascular diseases, diabetes, immunological diseases and other fields. Cabergoline, part of its early development, is still used on the global market today and has become one of the standard medications for the treatment of hyperprolactinemia and Parkinson's disease.

The manufacturers of cabergoline evolved over the years, and many other pharmaceutical companies besides Sanofi began producing the drug. Today, both generic and brand-name versions of cabergoline are manufactured and sold by multiple pharmaceutical companies around the world. These companies usually produce based on drug approvals and market needs in different countries.

One of the trade names for cabergoline isDostinex, a brand name of Sanofi. Sanofi has marketed cabergoline in many countries and regions around the world through this brand and ensures that its quality control and production standards comply with global drug regulatory requirements. As cabergoline became more widely available, several other pharmaceutical companies began producing generic versions, which often entered the market at lower prices, making the drug available to more patients.

Reference materials:https://my.clevelandclinic.org/health/drugs/20863-cabergoline-tablets